Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Federation Bio.

    Client Virtual Booth

    FEDERATION BIO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Federation Bio
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    South San Francisco, California 94080, US
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.federation.bio/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Kanvas Biosciences Acquires Federation Bio Assets to Scale the Discovery, Development and Manufacturing of Microbiome-Based Therapeutics

    Details:

    As part of the asset acquisition, Kanvas Biosciences will advance two core initiatives that improve the treatment of prevalent diseases: Immuno-oncology program and Inflammatory Bowel Disease program.


    Lead Product(s): Undisclosed

    Therapeutic Area: Immunology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Kanvas Biosciences

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition October 11, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    MD Anderson and Federation Bio Announce Collaboration to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers

    Details:

    The collaboration will join MD Anderson's expertise and capabilities with Fed Bio's proprietary ACT bacterial cell therapy platform to design and manufacture a complex, synthetic microbiome-based therapy.


    Lead Product(s): Microbiome-based Therapy

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Large molecule

    Partner/Sponsor/Collaborator: MD Anderson

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration February 01, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Federation Bio Administers First Dose in Phase 1 Clinical Trial Evaluating Investigational Bacterial Cell Therapy

    Details:

    FB-001 is an investigational, oral therapy consisting of 148 bacterial strains isolated from multiple healthy donors. It is the first rationally designed complex consortium at this scale to enter clinical studies.


    Lead Product(s): FB-001

    Therapeutic Area: Gastroenterology Product Name: FB-001

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 08, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies

    Details:

    Federation Bio will use proceeds from the financing to build out its in-house development process to enable Phase 1/2 manufacturing and advance its lead program into the clinic.


    Lead Product(s): Human gut microbiome

    Therapeutic Area: Nephrology Product Name: Undisclosed

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Horizons Ventures

    Deal Size: $50.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing October 06, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search